Search
Bremelanotide
go.drugbank.com/drugs/DB11653Approved[A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. … [A179686] The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.
Chymotrypsin
go.drugbank.com/drugs/DB09375ApprovedInvestigationalVet approvedWithdrawnChymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein synthesized by the exocrine pancreas [A32637]. … Chymotrypsin contains both the catalytic triad and oxyanion hole, and the tertiary structure of chymotrypsin is similar to [DB11237] [A32642].
Diamorphine
go.drugbank.com/drugs/DB01452ApprovedIllicitAs heroin, it is illegal to manufacture, possess, or sell in the United States and the UK. However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom. … Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs.
Synonyms: O,O'-DiacetylmorphineCefoperazone
go.drugbank.com/drugs/DB01329ApprovedInvestigationalWithdrawnIt is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis … Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against <i>Pseudomonas</i> infections.
Bepotastine
go.drugbank.com/drugs/DB04890ApprovedBepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the … Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor.
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnIt was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. … In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985]
Secukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.
Alprenolol
go.drugbank.com/drugs/DB00866ApprovedWithdrawnAlprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.
Categories: Beta Blocking Agents, Non-SelectiveSynonyms: 1-(o-Allylphenoxy)-3-(isopropylamino)-2-propanolCefpodoxime
go.drugbank.com/drugs/DB01416ApprovedInvestigationalVet approvedCommonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.
Pixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnIt is similar in structure to anthracyclines such as mitoxantrone, but exerts fewer toxic effects on cardiac tissue. [2] The lower cardio-toxic effects of pixantrone may be explained, in part, by its redox … It is currently being tested in Phase III trials. [2] Although pixantrone has not yet received FDA approval in the United States, it has been granted conditional marketing approval by the European Union